4-乙氧基-N-苯基苯甲酰胺 | 15437-13-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-乙氧基-N-苯基苯甲酰胺
• 英文名称: N-phenyl-4-ethoxybenzamide
• 英文别名: 4-ethoxy-N-phenylbenzamide；N--anilin；4-ethoxy-benzoic acid anilide；4-Aethoxy-benzoesaeure-anilid
• CAS: 15437-13-5
• 化学式: C₁₅H₁₅NO₂
• mdl: MFCD01032759
• 分子量: 241.29
• InChiKey: VCHIXAVDNIQOPN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.133
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2924299090

反应信息

• 作为产物：
  描述：

  对乙氧基苯甲酸乙酯 在 盐酸 、 乙醚 、 一水合肼 、 sodium nitrite 作用下， 生成 4-乙氧基-N-苯基苯甲酰胺
  参考文献：
  名称：

  Curtius; Ulmer, Journal fur praktische Chemie (Leipzig 1954), 1930, vol. <2> 125, p. 54,58

  摘要：

  DOI：

文献信息

• Visible-Light-Promoted Iron-Catalyzed <i>N</i>-Arylation of Dioxazolones with Arylboronic Acids
  作者：Jing-Jing Tang、Xiaoqiang Yu、Yoshinori Yamamoto、Ming Bao

  DOI：10.1021/acscatal.1c04538

  日期：2021.11.19

  A visible-light-promoted and simple iron salt-catalyzed N-arylation was achieved efficiently under external photosensitizer-free conditions. Arylboronic acids and bench-stable dioxazolones were used for this cross-coupling reaction. This reaction features high reactivity, wide substrate scope, good functional group tolerance, simple operation procedure, and mild reaction conditions. Preliminary mechanistic

  可见光促进的和简单的铁盐-催化Ñ -arylation被外部自由光敏剂条件下有效地实现。芳基硼酸和长期稳定的二恶唑酮用于这种交叉偶联反应。该反应具有反应活性高、底物范围广、官能团耐受性好、操作步骤简单、反应条件温和等特点。进行了初步机制研究以支持激进途径。这种方法可能有助于改变铁催化的 C-N 键构建和氮烯转移化学的范式。
• Efficient Pd-Catalyzed Hydrodehalogenation of o-Haloanilides in Water
  作者：Zewei Mao、Yanling Tang、Minxin Li、Hui Gao、Gaoxiong Rao

  DOI：10.1055/s-0040-1707116

  日期：2020.7

  In the present work, we have developed a practical methodology for the hydrodehalogenation of o-haloanilides using PdCl2 at 100 °C under mild conditions in water. The catalytic system could selectively dehalogenate both aryl chloride and aryl bromide and exhibit a broad functional group tolerance.

  在这项研究中，我们开发了一种实用的方法，使用PdCl2在水中在100°C下，在温和条件下对邻卤苯胺进行脱卤反应。该催化系统能够选择性地去卤化芳基氯和芳基溴，并具有广泛的官能团容忍性。
• TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS
  申请人：Tao Chunlin

  公开号：US20120172361A1

  公开（公告）日：2012-07-05

  Compounds of the formula (I) and formula (II) and pharmaceutically acceptable salts thereof.

  公式（I）和公式（II）的化合物及其药学上可接受的盐。
• SUBSTITUTED BENZAMIDE DERIVATIVES
  申请人：F. Hoffmann-La Roche AG

  公开号：EP3187490A1

  公开（公告）日：2017-07-05

  The invention relates to compounds of formula wherein R is hydrogen or lower alkyl; R1 is -(CH2)n-(O)o-heterocycloalkyl or -C(O)-heterocycloalkyl, wherein the heterocycloalkyl group is optionally substituted by lower alkyl, hydroxy, halogen or by -(CH2)p-aryl; n is 0, 1 or 2; o is 0 or 1; p is 0, 1 or 2; R2 is CF3, cycloalkyl, optionally substituted by lower alkoxy or halogen, or is indan-2-yl, or is heterocycloalkyl, optionally substituted by heteroaryl, or is aryl or heteroaryl, wherein the aromatic rings are optionally substituted by one or two substituents, selected from lower alkyl, halogen, heteroaryl, hydroxy, CF3, OCF3, OCH2CF3, OCH2-cycloalkyl, OCH2C(CH2OH)(CH2Cl)(CH3), S-lower alkyl, lower alkoxy, CH2-lower alkoxy, lower alkinyl or cyano, or by-C(O)-phenyl, -O-phenyl, -O-CH2-phenyl, phenyl or -CH2-phenyl, and wherein the phenyl rings may optionally be substituted by halogen, -C(O)-lower alkyl, -C(O)OH or -C(O)O-lower alkyl, or the aromatic rings are optionally substituted by heterocycloalkyl, OCH2-oxetan-3-yl or O-tetrahydropyran-4-yl, optionally substituted by lower alkyl; X is a bond; Y is a bond or -CH2- R' is hydrogen or lower alkyl, R" is hydrogen, lower alkyl, CF3, lower alkoxy, q is 0, 1, 2 or 3; or to a pharmaceutically suitable acid addition salt thereof. It has now been found that the compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

  本发明涉及式化合物 式中 R 是氢或低级烷基； R1 是-(CH2)n-(O)o-杂环烷基或-C(O)-杂环烷基，其中杂环烷基任选被低级烷基、羟基、卤素或-(CH2)p-芳基取代； n 为 0、1 或 2； o 为 0 或 1； p 为 0、1 或 2； R2 是 CF3、环烷基，可选择被低级烷氧基或卤素取代，或者是茚-2-基，或者是杂环烷基，可选择被杂芳基取代、 或芳基或杂芳基，其中芳环可选择被一个或两个取代基取代，这些取代基可选 自低级烷基、卤素、杂芳基、羟基、CF3、OCF3、OCH2CF3、OCH2-环烷基、OCH2C(CH2OH)(CH2Cl)(CH3)低级烷氧基、CH2-低级烷氧基、低级烷基或氰基，或被-C(O)-苯基、-O-苯基、-O-CH2-苯基、苯基或-CH2-苯基取代，其中苯基环可任选被卤素、-C(O)-低级烷基、-C(O)OH 或-C(O)O-低级烷基取代、 或芳香环可任选被杂环烷基、OCH2-氧杂环丁烷-3-基或 O-四氢吡喃-4-基（可任选被低级烷基取代）取代； X 是键； Y 是键或 -CH2- R' 是氢或低级烷基、 R" 是氢、低级烷基、CF3、低级烷氧基、 q 是 0、1、2 或 3； 或其药理上合适的酸加成盐。 现已发现，式 I 的化合物对痕量胺相关受体（TAARs），尤其是 TAAR1 具有良好的亲和力。 这些化合物可用于治疗抑郁症、焦虑症、双相情感障碍、注意力缺陷多动障碍（ADHD）、应激相关障碍、精神分裂症等精神障碍、帕金森病等神经系统疾病、阿尔茨海默病等神经退行性疾病、癫痫、偏头痛、高血压、药物滥用和其他疾病、偏头痛、高血压、药物滥用和代谢紊乱，如饮食紊乱、糖尿病、糖尿病并发症、肥胖症、血脂异常、能量消耗和同化紊乱、体温平衡紊乱和失调、睡眠和昼夜节律紊乱以及心血管疾病。
• Efficient method for the direct preparation of amides from carboxylic acids using tosyl chloride under solvent-free conditions
  作者：Ali Khalafi-Nezhad、Abolfath Parhami、Mohammad Navid Soltani Rad、Abdolkarim Zarea

  DOI：10.1016/j.tetlet.2005.08.021

  日期：2005.10

  A simple, clean and highly efficient solvent-free procedure for the preparation of primary, secondary, tertiary and aromatic amides is described from the direct reaction of carboxylic acids and silica-supported ammonium salts, triethylamine (TEA) and tosyl chloride (TsCI) as condensing agent. The reaction proceeds rapidly in high yields at room temperature. (c) 2005 Elsevier Ltd. All rights reserved.